Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to ...
The findings? Zepbound led to an average weightloss of 20.2 percent compared to Wegovy's 13.7 percent. We talked with healthcare experts to understand the study's findings, what sets these ...
Zepbound helps aid weightloss. Research consistently suggests people with overweight or obesity have more average weightloss on Zepbound than a placebo. The active ingredient in ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly. "Given the increased interest around obesity ...